hu.MAP 2.0: Complex View
Human Protein Complex Map
Search for a protein
Complex: HuMAP2_04499
Confidence: Medium High
Proteins| Genename | Protein Name | Links |
|---|---|---|
| ABL1 | Tyrosine-protein kinase ABL1 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 1) (Abelson tyrosine-protein kinase 1) (Proto-oncogene c-Abl) (p150) | UniProt NCBI |
| KRAS | GTPase KRas (K-Ras 2) (Ki-Ras) (c-K-ras) (c-Ki-ras) [Cleaved into: GTPase KRas, N-terminally processed] | UniProt NCBI |
| NRAS | GTPase NRas (Transforming protein N-Ras) | UniProt NCBI |
| HRAS | GTPase HRas (H-Ras-1) (Ha-Ras) (Transforming protein p21) (c-H-ras) (p21ras) [Cleaved into: GTPase HRas, N-terminally processed] | UniProt NCBI |
| RIN1 | Ras and Rab interactor 1 (Ras inhibitor JC99) (Ras interaction/interference protein 1) | UniProt NCBI |
Enrichments
| Term ID | Corrected Pval | Fraction Complex Coverage | Proteins | Term Name |
|---|---|---|---|---|
| WP:WP4223 | 4.238727456e-09 | 1.0 | KRAS HRAS RIN1 NRAS ABL1 | Ras Signaling |
| HP:0010815 | 9.3627397962e-09 | 0.6 | KRAS NRAS HRAS | Nevus sebaceous |
| HP:0010817 | 9.3627397962e-09 | 0.6 | KRAS NRAS HRAS | Linear nevus sebaceous |
| REAC:R-HSA-1169092 | 1.08753805614e-08 | 0.6 | KRAS NRAS HRAS | Activation of RAS in B cells |
| REAC:R-HSA-6802953 | 1.08753805614e-08 | 0.6 | KRAS NRAS HRAS | RAS signaling downstream of NF1 loss-of-function variants |
| KEGG:04014 | 1.29809643745e-08 | 1.0 | KRAS HRAS RIN1 NRAS ABL1 | Ras signaling pathway |
| REAC:R-HSA-112412 | 5.43659475995e-08 | 0.6 | KRAS NRAS HRAS | SOS-mediated signalling |
| REAC:R-HSA-9034864 | 5.43659475995e-08 | 0.6 | KRAS NRAS HRAS | Activated NTRK3 signals through RAS |
| REAC:R-HSA-9026519 | 5.43659475995e-08 | 0.6 | KRAS NRAS HRAS | Activated NTRK2 signals through RAS |
| REAC:R-HSA-9634635 | 5.43659475995e-08 | 0.6 | KRAS NRAS HRAS | Estrogen-stimulated signaling through PRKCZ |
| REAC:R-HSA-2428933 | 5.43659475995e-08 | 0.6 | KRAS NRAS HRAS | SHC-related events triggered by IGF1R |
| HP:0010816 | 9.36085359213e-08 | 0.6 | KRAS NRAS HRAS | Epidermal nevus |
| REAC:R-HSA-179812 | 9.51308232652e-08 | 0.6 | KRAS NRAS HRAS | GRB2 events in EGFR signaling |
| REAC:R-HSA-2179392 | 9.51308232652e-08 | 0.6 | KRAS NRAS HRAS | EGFR Transactivation by Gastrin |
| KEGG:05220 | 1.33164750997e-07 | 0.8 | KRAS HRAS NRAS ABL1 | Chronic myeloid leukemia |
| WP:WP2290 | 1.47866495656e-07 | 0.6 | KRAS NRAS HRAS | RalA downstream regulated genes |
| REAC:R-HSA-5654704 | 1.52193981994e-07 | 0.6 | KRAS NRAS HRAS | SHC-mediated cascade:FGFR3 |
| REAC:R-HSA-9028731 | 1.52193981994e-07 | 0.6 | KRAS NRAS HRAS | Activated NTRK2 signals through FRS2 and FRS3 |
| REAC:R-HSA-180336 | 1.52193981994e-07 | 0.6 | KRAS NRAS HRAS | SHC1 events in EGFR signaling |
| KEGG:04012 | 1.73841213182e-07 | 0.8 | KRAS HRAS NRAS ABL1 | ErbB signaling pathway |
| WP:WP673 | 1.82151113191e-07 | 0.8 | KRAS HRAS NRAS ABL1 | ErbB Signaling Pathway |
| REAC:R-HSA-8851805 | 2.28267971382e-07 | 0.6 | KRAS NRAS HRAS | MET activates RAS signaling |
| REAC:R-HSA-8853334 | 2.28267971382e-07 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR3 fusions in cancer |
| REAC:R-HSA-1250347 | 2.28267971382e-07 | 0.6 | KRAS NRAS HRAS | SHC1 events in ERBB4 signaling |
| REAC:R-HSA-5654706 | 3.26064244298e-07 | 0.6 | KRAS NRAS HRAS | FRS-mediated FGFR3 signaling |
| REAC:R-HSA-5655291 | 3.26064244298e-07 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR4 in disease |
| REAC:R-HSA-1963640 | 3.26064244298e-07 | 0.6 | KRAS NRAS HRAS | GRB2 events in ERBB2 signaling |
| WP:WP710 | 4.13226609885e-07 | 0.8 | KRAS HRAS NRAS ABL1 | DNA Damage Response (only ATM dependent) |
| REAC:R-HSA-5654719 | 4.48293159034e-07 | 0.6 | KRAS NRAS HRAS | SHC-mediated cascade:FGFR4 |
| REAC:R-HSA-5654688 | 4.48293159034e-07 | 0.6 | KRAS NRAS HRAS | SHC-mediated cascade:FGFR1 |
| HP:0001528 | 5.24049381299e-07 | 0.6 | KRAS NRAS HRAS | Hemihypertrophy |
| WP:WP4301 | 5.48118700158e-07 | 0.6 | KRAS NRAS HRAS | Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells |
| HP:0001680 | 5.70631169756e-07 | 0.8 | KRAS HRAS NRAS ABL1 | Coarctation of aorta |
| KEGG:04722 | 5.96187048479e-07 | 0.8 | KRAS HRAS NRAS ABL1 | Neurotrophin signaling pathway |
| REAC:R-HSA-5654699 | 5.97663979449e-07 | 0.6 | KRAS NRAS HRAS | SHC-mediated cascade:FGFR2 |
| REAC:R-HSA-171007 | 5.97663979449e-07 | 0.6 | KRAS NRAS HRAS | p38MAPK events |
| WP:WP732 | 7.65599689843e-07 | 0.6 | KRAS NRAS HRAS | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling |
| REAC:R-HSA-8849471 | 7.76884875116e-07 | 0.6 | KRAS NRAS HRAS | PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases |
| REAC:R-HSA-5654693 | 7.76884875116e-07 | 0.6 | KRAS NRAS HRAS | FRS-mediated FGFR1 signaling |
| REAC:R-HSA-9027284 | 7.76884875116e-07 | 0.6 | KRAS NRAS HRAS | Erythropoietin activates RAS |
| REAC:R-HSA-5654712 | 7.76884875116e-07 | 0.6 | KRAS NRAS HRAS | FRS-mediated FGFR4 signaling |
| REAC:R-HSA-5637810 | 7.76884875116e-07 | 0.6 | KRAS NRAS HRAS | Constitutive Signaling by EGFRvIII |
| REAC:R-HSA-5637812 | 7.76884875116e-07 | 0.6 | KRAS NRAS HRAS | Signaling by EGFRvIII in Cancer |
| HP:0001442 | 7.85994870532e-07 | 0.6 | KRAS NRAS HRAS | Somatic mosaicism |
| REAC:R-HSA-5654708 | 9.88662921473e-07 | 0.6 | KRAS NRAS HRAS | Downstream signaling of activated FGFR3 |
| REAC:R-HSA-5654700 | 9.88662921473e-07 | 0.6 | KRAS NRAS HRAS | FRS-mediated FGFR2 signaling |
| REAC:R-HSA-8853338 | 9.88662921473e-07 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR3 point mutants in cancer |
| REAC:R-HSA-9034015 | 9.88662921473e-07 | 0.6 | KRAS NRAS HRAS | Signaling by NTRK3 (TRKC) |
| REAC:R-HSA-5655332 | 9.88662921473e-07 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR3 in disease |
| REAC:R-HSA-210993 | 1.23570409997e-06 | 0.6 | KRAS NRAS HRAS | Tie2 Signaling |
| REAC:R-HSA-1250196 | 1.23570409997e-06 | 0.6 | KRAS NRAS HRAS | SHC1 events in ERBB2 signaling |
| REAC:R-HSA-5218921 | 1.5207132982e-06 | 0.6 | KRAS NRAS HRAS | VEGFR2 mediated cell proliferation |
| REAC:R-HSA-881907 | 1.5207132982e-06 | 0.6 | KRAS NRAS HRAS | Gastrin-CREB signalling pathway via PKC and MAPK |
| HP:0007206 | 1.54360737235e-06 | 0.6 | KRAS NRAS HRAS | Hemimegalencephaly |
| WP:WP2870 | 1.54385244607e-06 | 0.6 | KRAS NRAS HRAS | Extracellular vesicle-mediated signaling in recipient cells |
| REAC:R-HSA-5637815 | 1.84639431008e-06 | 0.6 | KRAS NRAS HRAS | Signaling by Ligand-Responsive EGFR Variants in Cancer |
| REAC:R-HSA-167044 | 1.84639431008e-06 | 0.6 | KRAS NRAS HRAS | Signalling to RAS |
| REAC:R-HSA-1236382 | 1.84639431008e-06 | 0.6 | KRAS NRAS HRAS | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants |
| REAC:R-HSA-5654716 | 1.84639431008e-06 | 0.6 | KRAS NRAS HRAS | Downstream signaling of activated FGFR4 |
| HP:0000267 | 2.05793576429e-06 | 0.6 | KRAS NRAS HRAS | Cranial asymmetry |
| WP:WP2643 | 2.19831769952e-06 | 0.6 | KRAS NRAS HRAS | Nanoparticle-mediated activation of receptor signaling |
| REAC:R-HSA-442982 | 2.21544983597e-06 | 0.6 | KRAS NRAS HRAS | Ras activation upon Ca2+ influx through NMDA receptor |
| REAC:R-HSA-5654696 | 2.21544983597e-06 | 0.6 | KRAS NRAS HRAS | Downstream signaling of activated FGFR2 |
| WP:WP437 | 2.3558861152e-06 | 0.8 | KRAS HRAS ABL1 RIN1 | EGF/EGFR Signaling Pathway |
| REAC:R-HSA-1643713 | 2.63058148282e-06 | 0.6 | KRAS NRAS HRAS | Signaling by EGFR in Cancer |
| WP:WP3844 | 2.72386132263e-06 | 0.6 | KRAS NRAS HRAS | PI3K-AKT-mTOR signaling pathway and therapeutic opportunities |
| KEGG:05206 | 2.80654604538e-06 | 0.8 | KRAS HRAS NRAS ABL1 | MicroRNAs in cancer |
| REAC:R-HSA-9006115 | 3.09448976434e-06 | 0.6 | KRAS NRAS HRAS | Signaling by NTRK2 (TRKB) |
| REAC:R-HSA-5654687 | 3.09448976434e-06 | 0.6 | KRAS NRAS HRAS | Downstream signaling of activated FGFR1 |
| WP:WP3676 | 3.32700170585e-06 | 0.6 | KRAS NRAS HRAS | BDNF-TrkB Signaling |
| HP:0004912 | 3.40426201827e-06 | 0.6 | KRAS NRAS HRAS | Hypophosphatemic rickets |
| KEGG:04360 | 3.42876450157e-06 | 0.8 | KRAS HRAS NRAS ABL1 | Axon guidance |
| REAC:R-HSA-5621575 | 3.60987410111e-06 | 0.6 | KRAS NRAS HRAS | CD209 (DC-SIGN) signaling |
| REAC:R-HSA-2424491 | 3.60987410111e-06 | 0.6 | KRAS NRAS HRAS | DAP12 signaling |
| WP:WP422 | 3.65933272422e-06 | 0.6 | KRAS NRAS HRAS | MAPK Cascade |
| WP:WP2828 | 4.78734040717e-06 | 0.6 | KRAS NRAS HRAS | Bladder Cancer |
| REAC:R-HSA-9006335 | 4.80586315819e-06 | 0.6 | KRAS NRAS HRAS | Signaling by Erythropoietin |
| HP:0011073 | 5.23627053194e-06 | 0.6 | KRAS NRAS HRAS | Abnormality of dental color |
| REAC:R-HSA-2172127 | 5.49186125546e-06 | 0.6 | KRAS NRAS HRAS | DAP12 interactions |
| KEGG:05219 | 6.69757781836e-06 | 0.6 | KRAS NRAS HRAS | Bladder cancer |
| KEGG:05216 | 6.69757781836e-06 | 0.6 | KRAS NRAS HRAS | Thyroid cancer |
| HP:0000337 | 6.95633979726e-06 | 0.8 | KRAS HRAS NRAS ABL1 | Broad forehead |
| REAC:R-HSA-2871796 | 7.0533398358e-06 | 0.6 | KRAS NRAS HRAS | FCERI mediated MAPK activation |
| REAC:R-HSA-442742 | 7.0533398358e-06 | 0.6 | KRAS NRAS HRAS | CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling |
| HP:0009720 | 7.62845613622e-06 | 0.6 | KRAS NRAS HRAS | Adenoma sebaceum |
| HP:0001548 | 7.62845613622e-06 | 0.6 | KRAS NRAS HRAS | Overgrowth |
| WP:WP2586 | 7.69263363807e-06 | 0.6 | KRAS NRAS HRAS | Aryl Hydrocarbon Receptor |
| REAC:R-HSA-186763 | 7.93420714119e-06 | 0.6 | KRAS NRAS HRAS | Downstream signal transduction |
| WP:WP4535 | 8.87288130353e-06 | 0.6 | KRAS NRAS HRAS | Envelope proteins and their potential roles in EDMD physiopathology |
| REAC:R-HSA-5654741 | 8.88541585136e-06 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR3 |
| REAC:R-HSA-187687 | 9.90965664735e-06 | 0.6 | KRAS NRAS HRAS | Signalling to ERKs |
| REAC:R-HSA-5673000 | 9.90965664735e-06 | 0.6 | KRAS NRAS HRAS | RAF activation |
| HP:0006740 | 1.06552534153e-05 | 0.6 | KRAS NRAS HRAS | Transitional cell carcinoma of the bladder |
| WP:WP4539 | 1.08600279875e-05 | 0.6 | KRAS NRAS HRAS | Synaptic signaling pathways associated with autism spectrum disorder |
| REAC:R-HSA-5654743 | 1.10096191184e-05 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR4 |
| REAC:R-HSA-112399 | 1.21879917622e-05 | 0.6 | KRAS NRAS HRAS | IRS-mediated signalling |
| REAC:R-HSA-5655302 | 1.21879917622e-05 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR1 in disease |
| HP:0002212 | 1.24298757708e-05 | 0.6 | KRAS NRAS HRAS | Curly hair |
| HP:0002862 | 1.43910367231e-05 | 0.6 | KRAS NRAS HRAS | Bladder carcinoma |
| HP:0010615 | 1.43910367231e-05 | 0.6 | KRAS NRAS HRAS | Angiofibromas |
| HP:0001355 | 1.43910367231e-05 | 0.6 | KRAS NRAS HRAS | Megalencephaly |
| REAC:R-HSA-2428924 | 1.62204393343e-05 | 0.6 | KRAS NRAS HRAS | IGF1R signaling cascade |
| REAC:R-HSA-2428928 | 1.62204393343e-05 | 0.6 | KRAS NRAS HRAS | IRS-related events triggered by IGF1R |
| REAC:R-HSA-5655253 | 1.62204393343e-05 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR2 in disease |
| HP:0002816 | 1.65480236581e-05 | 0.6 | KRAS NRAS HRAS | Genu recurvatum |
| HP:0009725 | 1.65480236581e-05 | 0.6 | KRAS NRAS HRAS | Bladder neoplasm |
| REAC:R-HSA-1433557 | 1.77393158174e-05 | 0.6 | KRAS NRAS HRAS | Signaling by SCF-KIT |
| REAC:R-HSA-2404192 | 1.77393158174e-05 | 0.6 | KRAS NRAS HRAS | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) |
| HP:0001048 | 1.89101201992e-05 | 0.6 | KRAS NRAS HRAS | Cavernous hemangioma |
| HP:0010500 | 1.89101201992e-05 | 0.6 | KRAS NRAS HRAS | Hyperextensibility of the knee |
| REAC:R-HSA-74751 | 1.93500285918e-05 | 0.6 | KRAS NRAS HRAS | Insulin receptor signalling cascade |
| REAC:R-HSA-6802948 | 1.93500285918e-05 | 0.6 | KRAS NRAS HRAS | Signaling by high-kinase activity BRAF mutants |
| REAC:R-HSA-5654736 | 1.93500285918e-05 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR1 |
| WP:WP4205 | 1.9577165768e-05 | 0.6 | KRAS NRAS HRAS | MET in type 1 papillary renal cell carcinoma |
| CORUM:1700 | 2.0123342217e-05 | 0.4 | RIN1 HRAS | ABL2-HRAS-RIN1 complex |
| KEGG:04730 | 2.01601392523e-05 | 0.6 | KRAS NRAS HRAS | Long-term depression |
| HP:0001428 | 2.02635774077e-05 | 0.8 | KRAS HRAS NRAS ABL1 | Somatic mutation |
| REAC:R-HSA-5675221 | 2.10552596086e-05 | 0.6 | KRAS NRAS HRAS | Negative regulation of MAPK pathway |
| KEGG:04929 | 2.13438745038e-05 | 0.6 | KRAS NRAS HRAS | GnRH secretion |
| HP:0002132 | 2.14866062081e-05 | 0.6 | KRAS NRAS HRAS | Porencephalic cyst |
| KEGG:04664 | 2.25729723653e-05 | 0.6 | KRAS NRAS HRAS | Fc epsilon RI signaling pathway |
| KEGG:04370 | 2.25729723653e-05 | 0.6 | KRAS NRAS HRAS | VEGF signaling pathway |
| KEGG:04213 | 2.38482793692e-05 | 0.6 | KRAS NRAS HRAS | Longevity regulating pathway - multiple species |
| KEGG:05213 | 2.51706417018e-05 | 0.6 | KRAS NRAS HRAS | Endometrial cancer |
| WP:WP4155 | 2.52916810244e-05 | 0.6 | KRAS NRAS HRAS | Endometrial cancer |
| WP:WP4341 | 2.65535825723e-05 | 0.6 | KRAS NRAS HRAS | Non-genomic actions of 1,25 dihydroxyvitamin D3 |
| REAC:R-HSA-5674135 | 2.67648652633e-05 | 0.6 | KRAS NRAS HRAS | MAP2K and MAPK activation |
| WP:WP3303 | 2.92016358744e-05 | 0.6 | KRAS NRAS HRAS | RAC1/PAK1/p38/MMP2 Pathway |
| KEGG:05221 | 2.94285173463e-05 | 0.6 | KRAS NRAS HRAS | Acute myeloid leukemia |
| REAC:R-HSA-1227986 | 3.10929802736e-05 | 0.6 | KRAS NRAS HRAS | Signaling by ERBB2 |
| KEGG:05218 | 3.25178756029e-05 | 0.6 | KRAS NRAS HRAS | Melanoma |
| KEGG:04917 | 3.25178756029e-05 | 0.6 | KRAS NRAS HRAS | Prolactin signaling pathway |
| KEGG:04137 | 3.25178756029e-05 | 0.6 | KRAS NRAS HRAS | Mitophagy - animal |
| KEGG:04720 | 3.25178756029e-05 | 0.6 | KRAS NRAS HRAS | Long-term potentiation |
| REAC:R-HSA-177929 | 3.34215806492e-05 | 0.6 | KRAS NRAS HRAS | Signaling by EGFR |
| HP:0003109 | 3.41219105177e-05 | 0.6 | KRAS NRAS HRAS | Hyperphosphaturia |
| KEGG:05211 | 3.41403204501e-05 | 0.6 | KRAS NRAS HRAS | Renal cell carcinoma |
| KEGG:05223 | 3.58157342459e-05 | 0.6 | KRAS NRAS HRAS | Non-small cell lung cancer |
| REAC:R-HSA-6802955 | 3.58634423945e-05 | 0.6 | KRAS NRAS HRAS | Paradoxical activation of RAF signaling by kinase inactive BRAF |
| REAC:R-HSA-6802946 | 3.58634423945e-05 | 0.6 | KRAS NRAS HRAS | Signaling by moderate kinase activity BRAF mutants |
| WP:WP4255 | 3.65771562028e-05 | 0.6 | KRAS NRAS HRAS | Non-small cell lung cancer |
| HP:0002748 | 3.79094101603e-05 | 0.6 | KRAS NRAS HRAS | Rickets |
| REAC:R-HSA-9006927 | 4.10976418258e-05 | 0.6 | KRAS NRAS HRAS | Signaling by Non-Receptor Tyrosine Kinases |
| REAC:R-HSA-8848021 | 4.10976418258e-05 | 0.6 | KRAS NRAS HRAS | Signaling by PTK6 |
| REAC:R-HSA-1236394 | 4.10976418258e-05 | 0.6 | KRAS NRAS HRAS | Signaling by ERBB4 |
| KEGG:04662 | 4.11682217947e-05 | 0.6 | KRAS NRAS HRAS | B cell receptor signaling pathway |
| KEGG:05230 | 4.11682217947e-05 | 0.6 | KRAS NRAS HRAS | Central carbon metabolism in cancer |
| KEGG:05214 | 4.30639421271e-05 | 0.6 | KRAS NRAS HRAS | Glioma |
| HP:0012599 | 4.63036319887e-05 | 0.6 | KRAS NRAS HRAS | Abnormal urine phosphate concentration |
| HP:0005600 | 4.64766403483e-05 | 0.4 | NRAS HRAS | Congenital giant melanocytic nevus |
| HP:0025510 | 4.64766403483e-05 | 0.4 | NRAS HRAS | Nevus spilus |
| REAC:R-HSA-375165 | 5.30427262701e-05 | 0.6 | KRAS NRAS HRAS | NCAM signaling for neurite out-growth |
| KEGG:01521 | 5.56685456996e-05 | 0.6 | KRAS NRAS HRAS | EGFR tyrosine kinase inhibitor resistance |
| WP:WP2261 | 5.91038759519e-05 | 0.6 | KRAS NRAS HRAS | Signaling Pathways in Glioblastoma |
| HP:0100555 | 6.1081767866e-05 | 0.6 | KRAS NRAS HRAS | Asymmetric growth |
| REAC:R-HSA-1226099 | 6.33776832781e-05 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR in disease |
| REAC:R-HSA-186797 | 6.70990066737e-05 | 0.6 | KRAS NRAS HRAS | Signaling by PDGF |
| KEGG:05235 | 7.05133054154e-05 | 0.6 | KRAS NRAS HRAS | PD-L1 expression and PD-1 checkpoint pathway in cancer |
| WP:WP35 | 7.07040269841e-05 | 0.6 | KRAS NRAS HRAS | G Protein Signaling Pathways |
| HP:0002148 | 7.24995537039e-05 | 0.6 | KRAS NRAS HRAS | Hypophosphatemia |
| WP:WP231 | 7.31920604822e-05 | 0.6 | KRAS NRAS HRAS | TNF alpha Signaling Pathway |
| KEGG:04912 | 7.32179527008e-05 | 0.6 | KRAS NRAS HRAS | GnRH signaling pathway |
| REAC:R-HSA-6802949 | 7.49721357414e-05 | 0.6 | KRAS NRAS HRAS | Signaling by RAS mutants |
| KEGG:04211 | 7.59906976524e-05 | 0.6 | KRAS NRAS HRAS | Longevity regulating pathway |
| KEGG:05210 | 7.59906976524e-05 | 0.6 | KRAS NRAS HRAS | Colorectal cancer |
| KEGG:04540 | 8.17438290338e-05 | 0.6 | KRAS NRAS HRAS | Gap junction |
| REAC:R-HSA-5654738 | 8.34369774361e-05 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR2 |
| HP:0001679 | 8.37690448493e-05 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal aortic morphology |
| REAC:R-HSA-74752 | 8.78979375366e-05 | 0.6 | KRAS NRAS HRAS | Signaling by Insulin receptor |
| KEGG:04625 | 9.41040777628e-05 | 0.6 | KRAS NRAS HRAS | C-type lectin receptor signaling pathway |
| KEGG:04916 | 9.73769288451e-05 | 0.6 | KRAS NRAS HRAS | Melanogenesis |
| KEGG:05231 | 9.73769288451e-05 | 0.6 | KRAS NRAS HRAS | Choline metabolism in cancer |
| KEGG:04660 | 0.000100724565592 | 0.6 | KRAS NRAS HRAS | T cell receptor signaling pathway |
| KEGG:05215 | 0.000100724565592 | 0.6 | KRAS NRAS HRAS | Prostate cancer |
| KEGG:01522 | 0.000100724565592 | 0.6 | KRAS NRAS HRAS | Endocrine resistance |
| KEGG:04933 | 0.000104147822452 | 0.6 | KRAS NRAS HRAS | AGE-RAGE signaling pathway in diabetic complications |
| REAC:R-HSA-6802952 | 0.000107327354708 | 0.6 | KRAS NRAS HRAS | Signaling by BRAF and RAF fusions |
| WP:WP4321 | 0.000107720319002 | 0.6 | KRAS NRAS HRAS | Thermogenesis |
| WP:WP4541 | 0.00011435890921 | 0.6 | KRAS NRAS HRAS | Hippo-Merlin Signaling Dysregulation |
| HP:0000269 | 0.000115080494194 | 0.6 | KRAS NRAS HRAS | Prominent occiput |
| KEGG:04726 | 0.000118613727961 | 0.6 | KRAS NRAS HRAS | Serotonergic synapse |
| KEGG:04725 | 0.000122427590077 | 0.6 | KRAS NRAS HRAS | Cholinergic synapse |
| REAC:R-HSA-9009391 | 0.000123638575202 | 0.6 | KRAS NRAS HRAS | Extra-nuclear estrogen signaling |
| REAC:R-HSA-190236 | 0.00012942105654 | 0.6 | KRAS NRAS HRAS | Signaling by FGFR |
| REAC:R-HSA-5658442 | 0.00012942105654 | 0.6 | KRAS NRAS HRAS | Regulation of RAS by GAPs |
| KEGG:04650 | 0.000134356221711 | 0.6 | KRAS NRAS HRAS | Natural killer cell mediated cytotoxicity |
| HP:0003196 | 0.000138650182281 | 0.8 | KRAS HRAS NRAS ABL1 | Short nose |
| HP:0002671 | 0.00014151146773 | 0.6 | KRAS NRAS HRAS | Basal cell carcinoma |
| HP:0000085 | 0.000151144719414 | 0.6 | KRAS NRAS HRAS | Horseshoe kidney |
| HP:0000995 | 0.000151144719414 | 0.6 | KRAS NRAS HRAS | Melanocytic nevus |
| HP:0100529 | 0.000161204760273 | 0.6 | KRAS NRAS HRAS | Abnormal blood phosphate concentration |
| REAC:R-HSA-187037 | 0.000167928044622 | 0.6 | KRAS NRAS HRAS | Signaling by NTRK1 (TRKA) |
| REAC:R-HSA-6806834 | 0.000167928044622 | 0.6 | KRAS NRAS HRAS | Signaling by MET |
| REAC:R-HSA-438064 | 0.000167928044622 | 0.6 | KRAS NRAS HRAS | Post NMDA receptor activation events |
| HP:0100625 | 0.000171700780036 | 0.6 | KRAS NRAS HRAS | Enlarged thorax |
| HP:0011061 | 0.000175927994119 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of dental structure |
| KEGG:04071 | 0.000179646697347 | 0.6 | KRAS NRAS HRAS | Sphingolipid signaling pathway |
| HP:0000474 | 0.000194037496444 | 0.6 | KRAS NRAS HRAS | Thickened nuchal skin fold |
| HP:0010614 | 0.000194037496444 | 0.6 | KRAS NRAS HRAS | Fibroma |
| REAC:R-HSA-1168372 | 0.000197423805207 | 0.6 | KRAS NRAS HRAS | Downstream signaling events of B Cell Receptor (BCR) |
| KEGG:04919 | 0.00020027593347 | 0.6 | KRAS NRAS HRAS | Thyroid hormone signaling pathway |
| REAC:R-HSA-6802957 | 0.000205300002873 | 0.6 | KRAS NRAS HRAS | Oncogenic MAPK signaling |
| KEGG:04068 | 0.000205667969449 | 0.6 | KRAS NRAS HRAS | FoxO signaling pathway |
| WP:WP3929 | 0.000206095076976 | 0.6 | KRAS NRAS HRAS | Chemokine signaling pathway |
| KEGG:05200 | 0.000217862252065 | 0.8 | KRAS HRAS NRAS ABL1 | Pathways in cancer |
| HP:0012316 | 0.000218228311494 | 0.6 | KRAS NRAS HRAS | Fibrous tissue neoplasm |
| KEGG:04926 | 0.000240055495634 | 0.6 | KRAS NRAS HRAS | Relaxin signaling pathway |
| KEGG:04915 | 0.000252313158511 | 0.6 | KRAS NRAS HRAS | Estrogen signaling pathway |
| REAC:R-HSA-442755 | 0.00025697910325 | 0.6 | KRAS NRAS HRAS | Activation of NMDA receptors and postsynaptic events |
| KEGG:04550 | 0.000258594789588 | 0.6 | KRAS NRAS HRAS | Signaling pathways regulating pluripotency of stem cells |
| KEGG:04371 | 0.000264979384683 | 0.6 | KRAS NRAS HRAS | Apelin signaling pathway |
| KEGG:04910 | 0.000271467766564 | 0.6 | KRAS NRAS HRAS | Insulin signaling pathway |
| KEGG:04210 | 0.000271467766564 | 0.6 | KRAS NRAS HRAS | Apoptosis |
| HP:0100031 | 0.000272465709143 | 0.6 | KRAS NRAS HRAS | Neoplasm of the thyroid gland |
| KEGG:04072 | 0.000278060757653 | 0.6 | KRAS NRAS HRAS | Phospholipase D signaling pathway |
| HP:0010759 | 0.000278784943944 | 0.4 | NRAS HRAS | Prominence of the premaxilla |
| HP:0002861 | 0.000287298458388 | 0.6 | KRAS NRAS HRAS | Melanoma |
| WP:WP4262 | 0.000290626512492 | 0.6 | KRAS NRAS HRAS | Breast cancer pathway |
| HP:0001357 | 0.000302658877703 | 0.6 | KRAS NRAS HRAS | Plagiocephaly |
| KEGG:05224 | 0.000305495250573 | 0.6 | KRAS NRAS HRAS | Breast cancer |
| KEGG:04062 | 0.000305495250573 | 0.6 | KRAS NRAS HRAS | Chemokine signaling pathway |
| KEGG:05226 | 0.000312623612064 | 0.6 | KRAS NRAS HRAS | Gastric cancer |
| HP:0004422 | 0.000318556115604 | 0.6 | KRAS NRAS HRAS | Biparietal narrowing |
| KEGG:04140 | 0.000327209764734 | 0.6 | KRAS NRAS HRAS | Autophagy - animal |
| REAC:R-HSA-4420097 | 0.000327410819085 | 0.6 | KRAS NRAS HRAS | VEGFA-VEGFR2 Pathway |
| REAC:R-HSA-166520 | 0.000327410819085 | 0.6 | KRAS NRAS HRAS | Signaling by NTRKs |
| WP:WP4666 | 0.000330006954152 | 0.6 | KRAS NRAS HRAS | Hepatitis B infection |
| KEGG:04921 | 0.000342240622109 | 0.6 | KRAS NRAS HRAS | Oxytocin signaling pathway |
| KEGG:05160 | 0.000349924863199 | 0.6 | KRAS NRAS HRAS | Hepatitis C |
| KEGG:04150 | 0.000415558284387 | 0.6 | KRAS NRAS HRAS | mTOR signaling pathway |
| REAC:R-HSA-194138 | 0.000422377343701 | 0.6 | KRAS NRAS HRAS | Signaling by VEGF |
| KEGG:04218 | 0.000424294655338 | 0.6 | KRAS NRAS HRAS | Cellular senescence |
| HP:0011425 | 0.000425724578531 | 0.6 | KRAS NRAS HRAS | Fetal ultrasound soft marker |
| REAC:R-HSA-983705 | 0.000448679555289 | 0.6 | KRAS NRAS HRAS | Signaling by the B Cell Receptor (BCR) |
| REAC:R-HSA-202733 | 0.000462229124052 | 0.6 | KRAS NRAS HRAS | Cell surface interactions at the vascular wall |
| HP:0002731 | 0.00046457916755 | 0.4 | KRAS NRAS | Decreased lymphocyte apoptosis |
| HP:0030886 | 0.00046457916755 | 0.4 | KRAS NRAS | Abnormal lymphocyte apoptosis |
| HP:0004097 | 0.0005039967211 | 0.8 | KRAS HRAS NRAS ABL1 | Deviation of finger |
| KEGG:05161 | 0.000518446983019 | 0.6 | KRAS NRAS HRAS | Hepatitis B |
| HP:0011004 | 0.000557024931373 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal systemic arterial morphology |
| KEGG:05225 | 0.000559677819772 | 0.6 | KRAS NRAS HRAS | Hepatocellular carcinoma |
| HP:0009484 | 0.000577947900247 | 0.8 | KRAS HRAS NRAS ABL1 | Deviation of the hand or of fingers of the hand |
| KEGG:05167 | 0.000625511303776 | 0.6 | KRAS NRAS HRAS | Kaposi sarcoma-associated herpesvirus infection |
| KEGG:05034 | 0.000636959120994 | 0.6 | KRAS NRAS HRAS | Alcoholism |
| HP:0000766 | 0.000667567988101 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of the sternum |
| HP:0040198 | 0.000696775152219 | 0.4 | NRAS HRAS | Non-medullary thyroid carcinoma |
| HP:0012209 | 0.000696775152219 | 0.4 | KRAS NRAS | Juvenile myelomonocytic leukemia |
| HP:0001054 | 0.000696775152219 | 0.4 | NRAS HRAS | Numerous nevi |
| KEGG:04015 | 0.000721004021602 | 0.6 | KRAS NRAS HRAS | Rap1 signaling pathway |
| REAC:R-HSA-2454202 | 0.000754665480287 | 0.6 | KRAS NRAS HRAS | Fc epsilon receptor (FCERI) signaling |
| HP:0001642 | 0.00076328835759 | 0.6 | KRAS NRAS HRAS | Pulmonic stenosis |
| HP:0011217 | 0.00076328835759 | 0.6 | KRAS NRAS HRAS | Abnormal shape of the occiput |
| HP:0012591 | 0.00076328835759 | 0.6 | KRAS NRAS HRAS | Abnormal urinary electrolyte concentration |
| HP:0000465 | 0.00076328835759 | 0.6 | KRAS NRAS HRAS | Webbed neck |
| HP:0000826 | 0.000822579716856 | 0.6 | KRAS NRAS HRAS | Precocious puberty |
| HP:0030448 | 0.000853340168558 | 0.6 | KRAS NRAS HRAS | Soft tissue sarcoma |
| REAC:R-HSA-5621481 | 0.000874143100407 | 0.6 | KRAS NRAS HRAS | C-type lectin receptors (CLRs) |
| HP:0100000 | 0.000884855881294 | 0.6 | KRAS NRAS HRAS | Early onset of sexual maturation |
| KEGG:04810 | 0.000910491071115 | 0.6 | KRAS NRAS HRAS | Regulation of actin cytoskeleton |
| KEGG:05205 | 0.000925161775741 | 0.6 | KRAS NRAS HRAS | Proteoglycans in cancer |
| KEGG:05203 | 0.000925161775741 | 0.6 | KRAS NRAS HRAS | Viral carcinogenesis |
| HP:0012311 | 0.00097535418756 | 0.4 | KRAS NRAS | Monocytosis |
| HP:0010758 | 0.00097535418756 | 0.4 | NRAS HRAS | Abnormality of the premaxilla |
| REAC:R-HSA-422475 | 0.00101311640921 | 0.8 | KRAS HRAS NRAS ABL1 | Axon guidance |
| REAC:R-HSA-416476 | 0.00102865345201 | 0.6 | KRAS NRAS HRAS | G alpha (q) signalling events |
| KEGG:05166 | 0.0010643020945 | 0.6 | KRAS NRAS HRAS | Human T-cell leukemia virus 1 infection |
| KEGG:05170 | 0.00109699385517 | 0.6 | KRAS NRAS HRAS | Human immunodeficiency virus 1 infection |
| HP:0003745 | 0.00112737333582 | 0.6 | KRAS NRAS HRAS | Sporadic |
| HP:0001974 | 0.00112737333582 | 0.6 | KRAS NRAS ABL1 | Leukocytosis |
| HP:0000293 | 0.00112737333582 | 0.6 | KRAS NRAS HRAS | Full cheeks |
| HP:0030962 | 0.00113333451199 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal morphology of the great vessels |
| WP:WP382 | 0.00113645450729 | 0.6 | KRAS NRAS HRAS | MAPK Signaling Pathway |
| KEGG:05163 | 0.00114726739179 | 0.6 | KRAS NRAS HRAS | Human cytomegalovirus infection |
| REAC:R-HSA-109582 | 0.0012064681881 | 0.8 | KRAS HRAS NRAS ABL1 | Hemostasis |
| HP:0100568 | 0.00124354263601 | 0.6 | KRAS NRAS HRAS | Neoplasm of the endocrine system |
| KEGG:04714 | 0.00127045127527 | 0.6 | KRAS NRAS HRAS | Thermogenesis |
| HP:0005523 | 0.00130029756695 | 0.4 | KRAS NRAS | Lymphoproliferative disorder |
| HP:0031654 | 0.00141044232307 | 0.6 | KRAS NRAS HRAS | Abnormal pulmonary valve physiology |
| HP:0003764 | 0.00149920031601 | 0.6 | KRAS NRAS HRAS | Nevus |
| HP:0000324 | 0.00163917495247 | 0.6 | KRAS NRAS HRAS | Facial asymmetry |
| HP:0012310 | 0.00167158658755 | 0.4 | KRAS NRAS | Abnormal monocyte count |
| HP:0012144 | 0.00167158658755 | 0.4 | KRAS NRAS | Abnormality monocyte morphology |
| HP:0010786 | 0.00168769249288 | 0.6 | KRAS NRAS HRAS | Urinary tract neoplasm |
| HP:0100242 | 0.00178757045499 | 0.6 | KRAS NRAS HRAS | Sarcoma |
| HP:0001028 | 0.00178757045499 | 0.6 | KRAS NRAS HRAS | Hemangioma |
| HP:0002514 | 0.00178757045499 | 0.6 | KRAS NRAS HRAS | Cerebral calcification |
| WP:WP3932 | 0.00181204447901 | 0.6 | KRAS NRAS HRAS | Focal Adhesion-PI3K-Akt-mTOR-signaling pathway |
| HP:0001305 | 0.00183894882664 | 0.6 | KRAS NRAS HRAS | Dandy-Walker malformation |
| HP:0005445 | 0.00189129875245 | 0.6 | KRAS NRAS HRAS | Widened posterior fossa |
| HP:0100742 | 0.00189129875245 | 0.6 | KRAS NRAS HRAS | Vascular neoplasm |
| HP:0003422 | 0.00194462919809 | 0.6 | KRAS NRAS HRAS | Vertebral segmentation defect |
| HP:0000326 | 0.00205426749297 | 0.6 | HRAS NRAS ABL1 | Abnormality of the maxilla |
| HP:0000418 | 0.00208920255027 | 0.4 | NRAS HRAS | Narrow nasal ridge |
| HP:0002729 | 0.00208920255027 | 0.4 | KRAS NRAS | Follicular hyperplasia |
| HP:0000506 | 0.00216793536231 | 0.6 | KRAS NRAS HRAS | Telecanthus |
| HP:0000098 | 0.00216793536231 | 0.6 | KRAS NRAS HRAS | Tall stature |
| HP:0002757 | 0.00216793536231 | 0.6 | KRAS NRAS HRAS | Recurrent fractures |
| HP:0000768 | 0.00228570439764 | 0.6 | KRAS NRAS HRAS | Pectus carinatum |
| HP:0002198 | 0.00228570439764 | 0.6 | KRAS NRAS HRAS | Dilated fourth ventricle |
| HP:0010950 | 0.00228570439764 | 0.6 | KRAS NRAS HRAS | Abnormality of the fourth ventricle |
| HP:0000218 | 0.00231811633149 | 0.8 | KRAS HRAS NRAS ABL1 | High palate |
| KEGG:04010 | 0.00232977147301 | 0.6 | KRAS NRAS HRAS | MAPK signaling pathway |
| REAC:R-HSA-112314 | 0.00234614610155 | 0.6 | KRAS NRAS HRAS | Neurotransmitter receptors and postsynaptic signal transmission |
| HP:0007400 | 0.00234614920866 | 0.6 | KRAS NRAS HRAS | Irregular hyperpigmentation |
| HP:0002350 | 0.00234614920866 | 0.6 | KRAS NRAS HRAS | Cerebellar cyst |
| HP:0011772 | 0.00240764613107 | 0.6 | KRAS NRAS HRAS | Abnormality of thyroid morphology |
| WP:WP4172 | 0.00254843909372 | 0.6 | KRAS NRAS HRAS | PI3K-Akt Signaling Pathway |
| HP:0006731 | 0.0025531267598 | 0.4 | NRAS HRAS | Follicular thyroid carcinoma |
| HP:0000932 | 0.00266433352331 | 0.6 | KRAS NRAS HRAS | Abnormality of the posterior cranial fossa |
| HP:0001909 | 0.00266433352331 | 0.6 | KRAS NRAS ABL1 | Leukemia |
| HP:0100542 | 0.00286833354554 | 0.6 | KRAS NRAS HRAS | Abnormal localization of kidney |
| HP:0008064 | 0.00286833354554 | 0.6 | KRAS NRAS HRAS | Ichthyosis |
| HP:0012056 | 0.0030633405246 | 0.4 | NRAS HRAS | Cutaneous melanoma |
| REAC:R-HSA-5673001 | 0.00319553479671 | 0.6 | KRAS NRAS HRAS | RAF/MAP kinase cascade |
| HP:0100763 | 0.0031998636837 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of the lymphatic system |
| HP:0002693 | 0.00330690735156 | 0.6 | KRAS NRAS HRAS | Abnormality of the skull base |
| REAC:R-HSA-5684996 | 0.00344863337702 | 0.6 | KRAS NRAS HRAS | MAPK1/MAPK3 signaling |
| HP:0000612 | 0.00362270778764 | 0.6 | KRAS NRAS HRAS | Iris coloboma |
| HP:0000179 | 0.00370466652798 | 0.6 | KRAS NRAS HRAS | Thick lower lip vermilion |
| HP:0002751 | 0.00370466652798 | 0.6 | KRAS NRAS HRAS | Kyphoscoliosis |
| REAC:R-HSA-8939211 | 0.00371466203946 | 0.6 | KRAS NRAS HRAS | ESR-mediated signaling |
| KEGG:04151 | 0.00373902224905 | 0.6 | KRAS NRAS HRAS | PI3K-Akt signaling pathway |
| HP:0010719 | 0.00404480197799 | 0.6 | KRAS NRAS HRAS | Abnormality of hair texture |
| HP:0000028 | 0.00406242032099 | 0.8 | KRAS HRAS NRAS ABL1 | Cryptorchidism |
| REAC:R-HSA-9607240 | 0.00410942027443 | 0.6 | KRAS NRAS HRAS | FLT3 Signaling |
| HP:0030724 | 0.00413295524356 | 0.6 | KRAS NRAS HRAS | Central nervous system cyst |
| HP:0010576 | 0.00413295524356 | 0.6 | KRAS NRAS HRAS | Intracranial cystic lesion |
| KEGG:05165 | 0.00420236199627 | 0.6 | KRAS NRAS HRAS | Human papillomavirus infection |
| HP:0004375 | 0.00422237396976 | 0.6 | KRAS NRAS HRAS | Neoplasm of the nervous system |
| HP:0011381 | 0.00422256197273 | 0.4 | KRAS NRAS | Aplasia of the semicircular canal |
| HP:0012324 | 0.00487153229182 | 0.4 | KRAS NRAS | Myeloid leukemia |
| HP:0100827 | 0.00487153229182 | 0.4 | KRAS NRAS | Lymphocytosis |
| HP:0010647 | 0.00498434077123 | 0.6 | KRAS ABL1 HRAS | Abnormal elasticity of skin |
| REAC:R-HSA-112315 | 0.005113781726 | 0.6 | KRAS NRAS HRAS | Transmission across Chemical Synapses |
| REAC:R-HSA-449836 | 0.005113781726 | 0.6 | KRAS NRAS HRAS | Other interleukin signaling |
| HP:0007379 | 0.00518810524287 | 0.6 | KRAS NRAS HRAS | Neoplasm of the genitourinary tract |
| HP:0008069 | 0.00529202687437 | 0.6 | KRAS NRAS HRAS | Neoplasm of the skin |
| HP:0001596 | 0.00539731984092 | 0.6 | KRAS NRAS HRAS | Alopecia |
| HP:0100702 | 0.00556671743772 | 0.4 | KRAS NRAS | Arachnoid cyst |
| HP:0100700 | 0.00556671743772 | 0.4 | KRAS NRAS | Abnormal arachnoid mater morphology |
| REAC:R-HSA-5683057 | 0.00574411448248 | 0.6 | KRAS NRAS HRAS | MAPK family signaling cascades |
| HP:0004426 | 0.00605836815217 | 0.6 | KRAS NRAS HRAS | Abnormality of the cheek |
| HP:0001010 | 0.00605836815217 | 0.6 | KRAS NRAS HRAS | Hypopigmentation of the skin |
| HP:0025015 | 0.00608677544742 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal vascular morphology |
| HP:0000606 | 0.0061735066244 | 0.6 | KRAS NRAS HRAS | Abnormality of the periorbital region |
| REAC:R-HSA-9006931 | 0.00634577840696 | 0.6 | KRAS NRAS HRAS | Signaling by Nuclear Receptors |
| HP:0002659 | 0.00640811720481 | 0.6 | KRAS NRAS HRAS | Increased susceptibility to fractures |
| HP:0001320 | 0.00652760684787 | 0.6 | KRAS NRAS HRAS | Cerebellar vermis hypoplasia |
| WP:WP2374 | 0.00667641105618 | 0.4 | KRAS HRAS | Oncostatin M Signaling Pathway |
| HP:0005692 | 0.00702033217347 | 0.6 | KRAS NRAS HRAS | Joint hyperflexibility |
| HP:0011380 | 0.00709565752293 | 0.4 | KRAS NRAS | Morphological abnormality of the semicircular canal |
| HP:0001561 | 0.00714724895655 | 0.6 | KRAS NRAS HRAS | Polyhydramnios |
| HP:0010766 | 0.00727567741272 | 0.6 | KRAS NRAS HRAS | Ectopic calcification |
| HP:0006482 | 0.00780468270807 | 0.6 | KRAS NRAS HRAS | Abnormality of dental morphology |
| HP:0006191 | 0.00792937512816 | 0.4 | KRAS HRAS | Deep palmar crease |
| HP:0011355 | 0.00846318146995 | 0.8 | KRAS HRAS NRAS ABL1 | Localized skin lesion |
| HP:0000938 | 0.00864502491522 | 0.6 | KRAS NRAS HRAS | Osteopenia |
| HP:0000589 | 0.00864502491522 | 0.6 | KRAS NRAS HRAS | Coloboma |
| HP:0000953 | 0.00879065778809 | 0.6 | KRAS NRAS HRAS | Hyperpigmentation of the skin |
| HP:0002859 | 0.00880923289202 | 0.4 | NRAS HRAS | Rhabdomyosarcoma |
| HP:0007477 | 0.0089379069678 | 0.6 | KRAS NRAS HRAS | Abnormal dermatoglyphics |
| HP:0011793 | 0.00894528033019 | 0.8 | KRAS HRAS NRAS ABL1 | Neoplasm by anatomical site |
| HP:0000765 | 0.00927785594799 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of the thorax |
| REAC:R-HSA-168249 | 0.0093160298358 | 0.8 | KRAS HRAS NRAS ABL1 | Innate Immune System |
| HP:0006817 | 0.00938943928499 | 0.6 | KRAS NRAS HRAS | Aplasia/Hypoplasia of the cerebellar vermis |
| HP:0011376 | 0.00973521215689 | 0.4 | KRAS NRAS | Morphological abnormality of the vestibule of the inner ear |
| HP:0000164 | 0.00997055798897 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of the dentition |
| HP:0007957 | 0.0100146377786 | 0.6 | KRAS NRAS HRAS | Corneal opacity |
| REAC:R-HSA-1266738 | 0.0103415798479 | 0.8 | KRAS HRAS NRAS ABL1 | Developmental Biology |
| HP:0002664 | 0.0106387322837 | 0.8 | KRAS HRAS NRAS ABL1 | Neoplasm |
| HP:0000035 | 0.0107010867528 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal testis morphology |
| HP:0000368 | 0.0111739705033 | 0.6 | KRAS NRAS HRAS | Low-set, posteriorly rotated ears |
| HP:0100886 | 0.0113397146668 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of globe location |
| HP:0003111 | 0.0116968496783 | 0.6 | KRAS NRAS HRAS | Abnormal blood ion concentration |
| HP:0000568 | 0.0118746757518 | 0.6 | KRAS NRAS HRAS | Microphthalmia |
| HP:0012471 | 0.0124188738287 | 0.6 | KRAS NRAS HRAS | Thick vermilion border |
| HP:0000290 | 0.0126308245049 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of the forehead |
| HP:0030791 | 0.012988055981 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal jaw morphology |
| HP:0000602 | 0.0131698060475 | 0.6 | KRAS NRAS HRAS | Ophthalmoplegia |
| HP:0002334 | 0.0135562849022 | 0.6 | KRAS NRAS HRAS | Abnormality of the cerebellar vermis |
| HP:0005105 | 0.0137250357747 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal nasal morphology |
| HP:0002088 | 0.0138760898251 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal lung morphology |
| HP:0009728 | 0.0138999712057 | 0.4 | NRAS HRAS | Neoplasm of striated muscle |
| HP:0002107 | 0.0138999712057 | 0.4 | ABL1 HRAS | Pneumothorax |
| HP:0004377 | 0.01395019732 | 0.6 | KRAS NRAS ABL1 | Hematological neoplasm |
| HP:0000178 | 0.0145551542008 | 0.6 | KRAS NRAS HRAS | Abnormality of lower lip |
| HP:0000962 | 0.0145551542008 | 0.6 | KRAS NRAS HRAS | Hyperkeratosis |
| HP:0001654 | 0.0147605976923 | 0.6 | KRAS NRAS HRAS | Abnormal heart valve morphology |
| HP:0000391 | 0.0150562782431 | 0.4 | KRAS NRAS | Thickened helices |
| HP:0001639 | 0.0156015562715 | 0.6 | KRAS NRAS HRAS | Hypertrophic cardiomyopathy |
| HP:0100887 | 0.0160336662282 | 0.6 | KRAS NRAS HRAS | Abnormality of globe size |
| HP:0000174 | 0.0162084757532 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal palate morphology |
| HP:0004396 | 0.0162585949147 | 0.4 | KRAS ABL1 | Poor appetite |
| REAC:R-HSA-5663202 | 0.016617401989 | 0.6 | KRAS NRAS HRAS | Diseases of signal transduction |
| HP:0040006 | 0.016696561986 | 0.6 | KRAS NRAS HRAS | Mortality/Aging |
| HP:0011420 | 0.016696561986 | 0.6 | KRAS NRAS HRAS | Age of death |
| HP:0031653 | 0.016696561986 | 0.6 | KRAS NRAS HRAS | Abnormal heart valve physiology |
| REAC:R-HSA-112316 | 0.0172109299174 | 0.6 | KRAS NRAS HRAS | Neuronal System |
| HP:0000767 | 0.0176082793452 | 0.6 | KRAS NRAS ABL1 | Pectus excavatum |
| HP:0002650 | 0.0176138590684 | 0.8 | KRAS HRAS NRAS ABL1 | Scoliosis |
| HP:0000597 | 0.0183132582526 | 0.6 | KRAS NRAS HRAS | Ophthalmoparesis |
| HP:0008070 | 0.0185523330327 | 0.6 | KRAS NRAS HRAS | Sparse hair |
| HP:0001911 | 0.0187934629081 | 0.6 | KRAS NRAS ABL1 | Abnormal granulocyte morphology |
| HP:0001382 | 0.0192819219746 | 0.6 | KRAS NRAS HRAS | Joint hypermobility |
| HP:0011792 | 0.0197787034757 | 0.6 | KRAS NRAS HRAS | Neoplasm by histology |
| HP:0000032 | 0.0201885758558 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of male external genitalia |
| HP:0001973 | 0.0215275853758 | 0.4 | KRAS NRAS | Autoimmune thrombocytopenia |
| HP:0011357 | 0.0215839586173 | 0.6 | KRAS NRAS HRAS | Abnormality of hair density |
| HP:0002815 | 0.0218504122467 | 0.6 | KRAS NRAS HRAS | Abnormality of the knee |
| HP:0002750 | 0.0218504122467 | 0.6 | KRAS NRAS HRAS | Delayed skeletal maturation |
| HP:0001167 | 0.0227034392536 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of finger |
| HP:0002890 | 0.0229596708254 | 0.4 | NRAS HRAS | Thyroid carcinoma |
| HP:0010461 | 0.0230334244903 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of the male genitalia |
| HP:0000811 | 0.0231442083502 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal external genitalia |
| HP:0010674 | 0.0234789391763 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of the curvature of the vertebral column |
| HP:0040019 | 0.023494903838 | 0.6 | KRAS NRAS ABL1 | Finger clinodactyly |
| HP:0010974 | 0.0237766929559 | 0.6 | KRAS NRAS ABL1 | Abnormal myeloid leukocyte morphology |
| HP:0010318 | 0.0244376541782 | 0.4 | KRAS NRAS | Aplasia/Hypoplasia of the abdominal wall musculature |
| HP:0000343 | 0.0255144387308 | 0.6 | KRAS NRAS HRAS | Long philtrum |
| HP:0012252 | 0.0256832651071 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal respiratory system morphology |
| HP:0011821 | 0.0258033904131 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of facial skeleton |
| HP:0002438 | 0.0258119768497 | 0.6 | KRAS NRAS HRAS | Cerebellar malformation |
| HP:0001873 | 0.0258119768497 | 0.6 | KRAS NRAS ABL1 | Thrombocytopenia |
| HP:0025033 | 0.0260448941493 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of digestive system morphology |
| HP:0012718 | 0.0260448941493 | 0.8 | KRAS HRAS NRAS ABL1 | Morphological abnormality of the gastrointestinal tract |
| HP:0007360 | 0.0261117985092 | 0.6 | KRAS NRAS HRAS | Aplasia/Hypoplasia of the cerebellum |
| HP:0001560 | 0.0261117985092 | 0.6 | KRAS NRAS HRAS | Abnormality of the amniotic fluid |
| HP:0011729 | 0.0274033471259 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of joint mobility |
| HP:0000476 | 0.0275312401623 | 0.4 | KRAS NRAS | Cystic hygroma |
| WP:WP51 | 0.0283719124097 | 0.4 | KRAS NRAS | Regulation of Actin Cytoskeleton |
| HP:0001547 | 0.0285935876638 | 0.6 | KRAS NRAS HRAS | Abnormality of the rib cage |
| REAC:R-HSA-9006934 | 0.0291077226575 | 0.6 | KRAS NRAS HRAS | Signaling by Receptor Tyrosine Kinases |
| HP:0011869 | 0.0291468055875 | 0.4 | KRAS NRAS | Abnormal platelet function |
| HP:0001631 | 0.0292374582023 | 0.6 | KRAS ABL1 HRAS | Atrial septal defect |
| HP:0011994 | 0.0295629530581 | 0.6 | KRAS ABL1 HRAS | Abnormal atrial septum morphology |
| WP:WP4239 | 0.0296692241758 | 0.4 | KRAS HRAS | Epithelial to mesenchymal transition in colorectal cancer |
| HP:0002002 | 0.0308081945037 | 0.4 | NRAS HRAS | Deep philtrum |
| HP:0012740 | 0.0308081945037 | 0.4 | NRAS HRAS | Papilloma |
| HP:0007440 | 0.0308081945037 | 0.4 | KRAS HRAS | Generalized hyperpigmentation |
| HP:0011873 | 0.0308888583123 | 0.6 | KRAS NRAS ABL1 | Abnormal platelet count |
| HP:0000927 | 0.0308888583123 | 0.6 | KRAS NRAS HRAS | Abnormality of skeletal maturation |
| GO:0002429 | 0.0309921425814 | 0.8 | KRAS HRAS NRAS ABL1 | immune response-activating cell surface receptor signaling pathway |
| HP:0011893 | 0.0315662834758 | 0.6 | KRAS NRAS ABL1 | Abnormal leukocyte count |
| HP:0011356 | 0.0315662834758 | 0.6 | KRAS NRAS HRAS | Regional abnormality of skin |
| HP:0005120 | 0.0326006997834 | 0.6 | KRAS ABL1 HRAS | Abnormal cardiac atrium morphology |
| HP:0011218 | 0.0336572505221 | 0.6 | KRAS NRAS HRAS | Abnormal shape of the frontal region |
| HP:0002007 | 0.0336572505221 | 0.6 | KRAS NRAS HRAS | Frontal bossing |
| HP:0001744 | 0.0336572505221 | 0.6 | KRAS NRAS ABL1 | Splenomegaly |
| WP:WP1984 | 0.0337317416567 | 0.4 | KRAS ABL1 | Integrated Breast Cancer Pathway |
| HP:0000238 | 0.0351008048623 | 0.6 | KRAS NRAS HRAS | Hydrocephalus |
| HP:0001629 | 0.035837654624 | 0.6 | KRAS ABL1 HRAS | Ventricular septal defect |
| GO:0019003 | 0.0358473364726 | 0.6 | KRAS NRAS HRAS | GDP binding |
| HP:0000820 | 0.0365846413997 | 0.6 | KRAS NRAS HRAS | Abnormality of the thyroid gland |
| GO:0007265 | 0.0376297096835 | 0.8 | KRAS HRAS NRAS ABL1 | Ras protein signal transduction |
| HP:0010438 | 0.0384968933304 | 0.6 | KRAS ABL1 HRAS | Abnormal ventricular septum morphology |
| HP:0000358 | 0.0400733062151 | 0.6 | KRAS NRAS HRAS | Posteriorly rotated ears |
| GO:0002768 | 0.0413212587053 | 0.8 | KRAS HRAS NRAS ABL1 | immune response-regulating cell surface receptor signaling pathway |
| HP:0001872 | 0.0421029548475 | 0.6 | KRAS NRAS ABL1 | Abnormal thrombocyte morphology |
| HP:0010991 | 0.0457467210618 | 0.4 | KRAS NRAS | Abnormal morphology of the abdominal musculature |
| HP:0001760 | 0.0458823387011 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormality of the foot |
| HP:0004322 | 0.0462525985754 | 0.8 | KRAS HRAS NRAS ABL1 | Short stature |
| HP:0002208 | 0.0478196851342 | 0.4 | KRAS NRAS | Coarse hair |
| HP:0001627 | 0.047946296424 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal heart morphology |
| HP:0040194 | 0.0481439167653 | 0.6 | KRAS NRAS HRAS | Increased head circumference |
| HP:0000256 | 0.0481439167653 | 0.6 | KRAS NRAS HRAS | Macrocephaly |
| HP:0011799 | 0.0485960101036 | 0.6 | KRAS NRAS HRAS | Abnormality of facial soft tissue |
| HP:0011368 | 0.0490508933376 | 0.6 | KRAS NRAS HRAS | Epidermal thickening |
| HP:0011297 | 0.0494900867638 | 0.8 | KRAS HRAS NRAS ABL1 | Abnormal digit morphology |
| HP:0011675 | 0.0495085746559 | 0.6 | KRAS NRAS HRAS | Arrhythmia |
| HP:0004415 | 0.0499382869304 | 0.4 | KRAS NRAS | Pulmonary artery stenosis |
| HP:0001641 | 0.0499382869304 | 0.4 | KRAS NRAS | Abnormal pulmonary valve morphology |
| CORUM:5922 | 0.0499494897235 | 0.2 | HRAS | RAF1-RAS complex, EGF induced |
| CORUM:2811 | 0.0499494897235 | 0.2 | ABL1 | BRCA1-cABL complex |
Edges
| Protein 1 | Protein 2 | Score | Precision | Evidence |
|---|---|---|---|---|
| KRAS | RIN1 | 0.761 | 0.749 | bioplex (RIN1) bioplex_WMM |
| ABL1 | RIN1 | 0.288 | 0.489 | bioplex (RIN1) bioplex_WMM |
| RIN1 | NRAS | 0.159 | 0.418 | bioplex (RIN1) bioplex_WMM boldt (RIN1) boldt_WMM |
| RIN1 | HRAS | 0.056 | 0.313 | bioplex (RIN1) bioplex_WMM |
| KRAS | ABL1 | 0.008 | 0.085 | bioplex_WMM WMM_only |
| KRAS | HRAS | 0.008 | 0.065 | bioplex_WMM WMM_only |
| ABL1 | NRAS | 0.007 | 0.01 | bioplex_WMM WMM_only |
| KRAS | NRAS | 0.007 | 0.01 | bioplex_WMM WMM_only |
| ABL1 | HRAS | 0.007 | 0.002 | bioplex_WMM WMM_only |
| NRAS | HRAS | 0.006 | 0.004 | bioplex_WMM WMM_only boldt_WMM |
Images
Click to enlarge
Complex HuMAP2_04499 has an average edge precision of 0.214 which is ranked 5957 out of all 6965 complexes.
Related Complexes
| Genename | Complexes |
|---|---|
| ABL1 | HuMAP2_03589 HuMAP2_04499 |
| KRAS | HuMAP2_01070 HuMAP2_03589 HuMAP2_04499 HuMAP2_05327 |
| NRAS | HuMAP2_03589 HuMAP2_04467 HuMAP2_04499 |
| HRAS | HuMAP2_03589 HuMAP2_04499 |
| RIN1 | HuMAP2_03589 HuMAP2_04499 HuMAP2_05327 |